Survodutide
BI 456906
An investigational dual glucagon and GLP-1 receptor agonist with high albumin binding, studied in trials for obesity and metabolic-associated liver disease. Its half-life supports once-weekly administration.
Half-life
~6-7 days, subcutaneous. Half-life is an educational pharmacology figure, drawn from public sources, and is not a schedule or dosing instruction.
Storage & handling
Supplied lyophilized; store cool, reconstitute before use, then refrigerate and protect from light.
References
- Zimmermann et al., Mol Metab 2022
- J Hepatology 2024 (cirrhosis PK)
Related in GLP-1 / Metabolic
Educational reference only, compiled from public sources. Not medical advice, diagnosis, treatment, or a dosing recommendation, and not a recommendation to use any compound. Many compounds listed are research materials not approved for human use. Consult a qualified professional.